Normal view MARC view ISBD view

Eclipse Stemless Shoulder Prosthesis versus Univers II Shoulder Prosthesis: A Multicenter, Prospective Randomized Controlled Trial.

MedStar author(s):

Citation: Journal of Shoulder & Elbow Surgery. 2020 Jul 21PMID: 32707325Institution: MedStar Union Memorial HospitalForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2020 ISSN:

1058-2746

Name of journal: Journal of shoulder and elbow surgeryAbstract: BACKGROUND: Total shoulder arthroplasty is an accepted treatment for glenohumeral osteoarthritis. The Arthrex Eclipse shoulder prosthesis is a stemless, canal-sparing, humeral prosthesis with bone ingrowth capacity on the trunnion as well as through the fenestrated hollow screw that provides both diaphyseal and metaphyseal load sharing and fixation.CONCLUSION: The Arthrex Eclipse shoulder prosthesis is a safe and effective humeral implant for patients with glenohumeral arthritis at two-year follow-up with no differences in outcomes when compared to the Univers II.LEVEL OF EVIDENCE: Level II; Randomized Controlled Trial; Treatment Study. Copyright (c) 2020. Published by Elsevier Inc.METHODS: 16 sites in the United States enrolled 327 patients (237 Eclipse, 90 Univers II) between 2013-2019. All patients had glenohumeral arthritis refractory to non-surgical care. Exclusion criteria were strict to avoid confounding factors such as severe patient co-morbidities, arthritis not consistent with osteoarthritis, and medical or prior surgical treatments that may affect outcomes. Patients were randomized to Eclipse or Univers II using block randomization.RESULTS: 149 Eclipse and 76 Univers II patients reached 2-year follow-up [139 (93.3%) Eclipse and 68 (89.5%) Univers II had complete data]. The success rate using the composite clinical success (CCS) score was 95% for Eclipse vs. 89.7% for Univers II group. No patient exhibited radiographic evidence of substantial humeral radiolucency, humeral migration, or subsidence at any point. There were 7 (3.2%) reoperations in the Eclipse and 3 (3.8%) in the Univers II group.All authors: Abboud J, Araghi A, Brandon TA, Brown J, Cohen B, Costouros J, Erickson BJ, Klassen J, Long N, McFadden E, Patterson P, Port J, Romeo AA, Sears B, Setter K, Smith M, Stein J, Tyndall W, Verma NNFiscal year: FY2021Digital Object Identifier:

https://dx.doi.org/10.1016/j.jse.2020.07.004

Date added to catalog: 2020-09-02

Holdings ( 1 )
Title notes ( 6 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	32707325	Available		32707325

BACKGROUND: Total shoulder arthroplasty is an accepted treatment for glenohumeral osteoarthritis. The Arthrex Eclipse shoulder prosthesis is a stemless, canal-sparing, humeral prosthesis with bone ingrowth capacity on the trunnion as well as through the fenestrated hollow screw that provides both diaphyseal and metaphyseal load sharing and fixation.

CONCLUSION: The Arthrex Eclipse shoulder prosthesis is a safe and effective humeral implant for patients with glenohumeral arthritis at two-year follow-up with no differences in outcomes when compared to the Univers II.

METHODS: 16 sites in the United States enrolled 327 patients (237 Eclipse, 90 Univers II) between 2013-2019. All patients had glenohumeral arthritis refractory to non-surgical care. Exclusion criteria were strict to avoid confounding factors such as severe patient co-morbidities, arthritis not consistent with osteoarthritis, and medical or prior surgical treatments that may affect outcomes. Patients were randomized to Eclipse or Univers II using block randomization.

RESULTS: 149 Eclipse and 76 Univers II patients reached 2-year follow-up [139 (93.3%) Eclipse and 68 (89.5%) Univers II had complete data]. The success rate using the composite clinical success (CCS) score was 95% for Eclipse vs. 89.7% for Univers II group. No patient exhibited radiographic evidence of substantial humeral radiolucency, humeral migration, or subsidence at any point. There were 7 (3.2%) reoperations in the Eclipse and 3 (3.8%) in the Univers II group.

English